Pictet North America Advisors 13F: New $665K Stake in BMY
Key Points
- Pictet North America Advisors disclosed a new position of 10,654 shares in Bristol-Myers Squibb Company BMY worth about $664,810 in an SEC filing on October 21, 2026.
- The pharmaceutical company trades around $61.15, below its 50-day moving average while holding a trailing twelve-month revenue of $49.19 billion.
- Wall Street analysts maintain a consensus buy rating on the stock with a mean price target of $65.42 ahead of the next earnings report on October 29, 2026.
Since the filing, $BMY is up 1.8% to date (from the $61.12 close on Oct 21, 2026).
Get Bristol-Myers Squibb Company text alerts
We text you when insiders, Congress, analysts or big funds move on $BMY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Bristol-Myers Squibb Company alert may contain errors. Disclosures
Pictet North America Advisors opened a new position in Bristol-Myers Squibb Company BMY, acquiring 10,654 shares worth about $664,810. The investment was revealed in a Form 13F filing filed with the Securities and Exchange Commission on October 21, 2026.
BMY
Bristol-Myers Squibb Company
What Changed in Pictet North America Advisors's Bristol-Myers Squibb Company Position
The firm established a brand-new holding in the drug manufacturer during the period, picking up 10,654 shares. The newly minted stake had a reported value of $664,810 as of the filing date.
Other Institutional Activity in Bristol-Myers Squibb Company
Other institutional investors have adjusted their portfolios around the drug maker recently. Euro Pacific Asset Management grew its holdings by 3,000 shares, ending with 3,000 shares worth about $202,680. Moody Lynn Lieberson & Walker grew its holdings by 58,236 shares, ending with 58,236 shares worth about $3.63 million. Fort Washington Investment Advisors cut its holdings by 588,083 shares, ending with 1,716,740 shares worth about $107.12 million. Hb Wealth Management grew its holdings by 22,867 shares, ending with 109,993 shares worth about $6.34 million. Woodline Partners grew its holdings by 51,521 shares, ending with 1,120,638 shares worth about $65.62 million.
Bristol-Myers Squibb Company Stock Up 0.2%
Bristol-Myers Squibb Company closed at $61.12 on October 21, 2026, and recently traded around $61.15. The stock sits below its 50-day moving average of $63.28 but remains above its 200-day moving average of $59.75. The shares trade below their 52-week high of $68.64 and well above their 52-week low of $42.52.
Recent Earnings
The pharmaceutical company generates $49.19 billion in trailing twelve-month revenue alongside earnings of $4.54 per share. The company posted a net profit margin of 18.9% and a return on equity of 46.6%. The company's next earnings report is scheduled for October 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
Analyst view held steady after the report.
-
EPS & revenue
EPS beat estimates by 10.4%. Revenue beat estimates by 4.3%.
-
Profit surprise
EBITDA missed by 13 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
- Analyst signal
-
Earnings quality
Gross margin up 4.7 points. Operating margin down 3.0 points. Positive free cash flow.
Earnings Call Summary
Bristol delivered a solid first quarter with revenue of 11.5 billion dollars, up 1 percent year over year, and earnings per share of 1.58 dollars, beating Wall Street by 10 percent. The growth portfolio grew 9 percent, led by strong performances from Eliquis at 4.1 billion dollars and Breyanzi up 53 percent. Management highlighted progress across pipeline programs including positive data for Pumitamig and upcoming late-year readouts for Factor XI inhibitor Milvexian and Cobenfy in Alzheimer's disease psychosis.
Guidance Bristol reaffirmed its 2026 financial targets and said the company is tracking toward the upper end of guidance. The management team noted strong momentum in the growth portfolio and multiple clinical readouts expected in the second half of the year, including Milvexian in atrial fibrillation and Cobenfy in Alzheimer's psychosis.
Underwhelming report. Mixed results that may lead to slightly lower expectations.
Dividend
Bristol-Myers Squibb Company pays an annual dividend of $2.52 per share, which translates to a dividend yield of 4.12%. The payout ratio sits at 55.3%.
Insider Buying and Selling at Bristol-Myers Squibb Company
Company insiders completed three notable transactions prior to the filing. Chief Financial Officer David Vincent Elkins disposed of 30,000 shares for a total value of $1.85 million on April 1, 2026. Officer Phil M Holzer sold 500 shares at a price of $67.50, totaling $33,750 on August 25, 2026. Officer Cristian Massacesi sold 6,249 shares at a price of $64.57, totaling $403,498 on September 9, 2026.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock ahead of the filing. On September 16, 2026, Piper Sandler reiterated its Overweight rating and raised its target from $75.00 to $82.00. On October 5, 2026, Leerink Partners downgraded the stock to Market Perform and cut its target from $73.00 to $59.00. On October 7, 2026, Morgan Stanley maintained an Underweight rating and raised its target from $40.00 to $41.00. On October 8, 2026, Cantor Fitzgerald maintained a Neutral rating and cut its target from $59.00 to $53.00. On October 13, 2026, Wells Fargo maintained an Equal-Weight rating and cut its target from $65.00 to $60.00. Overall, the stock holds a consensus buy rating and a mean price target of $65.42 across 24 analyst opinions.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, manufactures, and distributes biopharmaceutical products around the globe. Headquartered in Princeton, New Jersey, the healthcare giant focuses on treatments for oncology, hematology, immunology, cardiovascular diseases, and neuroscience conditions. Institutional interest remains active as the firm approaches its late-October financial update.
Bottom Line
Investors will watch the upcoming earnings release on October 29, 2026, for fresh details on financial performance and profit margins. Monitoring subsequent institutional filings will also show whether other funds follow Pictet North America Advisors into the healthcare name.
Related Filing Alerts
Source: Pictet North America Advisors's 13F filing on $BMY (Oct 21, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts